Literature DB >> 11574190

Macrolides: pharmacokinetics and pharmacodynamics.

F Van Bambeke1, P M Tulkens.   

Abstract

Three pharmacokinetic/pharmacodynamic parameters--(i) the peak concentration to the minimum inhibitory concentration ratio (C(max)/MIC); (ii) the area under the concentration-time curve to MIC ratio (AUC(24h)/MIC); and (iii) the time the concentration exceeds the MIC (T>MIC)--are important predictors of the clinical efficacy of antibiotics. For antibiotics with pronounced concentration-dependent killing, such as the fluoroquinolones or the aminoglycosides, C(max)/MIC and AUC(24)/MIC are the main factors that establish efficacy. Antibiotics with a weak, or no, concentration dependency generally have their efficacy linked to T>MIC, and these include the beta-lactams and the conventional macrolides. Antibiotics with weak concentration-dependent effects, but with prolonged persistent effects, such as tetracyclines and azithromycin, have their activity mostly related to the AUC(24)/MIC. By applying these concepts to current antibiotics, and also to the development of novel agents, it is possible to optimise their dosages and administration schedules. This will maximise therapeutic efficacy, may prevent or delay the emergence of bacterial resistance to antibiotics, and can certainly minimise side-effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574190     DOI: 10.1016/s0924-8579(01)00406-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  15 in total

1.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.

Authors:  Isabelle Cochereau; Amel Meddeb-Ouertani; Moncef Khairallah; Abdelouahed Amraoui; Khalid Zaghloul; Mihai Pop; Laurent Delval; Pascale Pouliquen; Radhika Tandon; Prashant Garg; Pablo Goldschmidt; Tristan Bourcier
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

3.  Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.

Authors:  Pin-Chuang Lai; Weiting Ho; Nidhi Jain; John D Walters
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

4.  In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.

Authors:  Takafumi Sato; Kazuhiro Tateda; Soichiro Kimura; Yoshikazu Ishii; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

Review 5.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Antimicrobial dosing in acute renal replacement.

Authors:  William H Fissell
Journal:  Adv Chronic Kidney Dis       Date:  2013-01       Impact factor: 3.620

7.  A clinical pathway for community-acquired pneumonia: an observational cohort study.

Authors:  Christopher R Frei; Allison M Bell; Kristi A Traugott; Terry C Jaso; Kelly R Daniels; Eric M Mortensen; Marcos I Restrepo; Christine U Oramasionwu; Andres D Ruiz; William R Mylchreest; Vanja Sikirica; Monika R Raut; Alan Fisher; Jeff R Schein
Journal:  BMC Infect Dis       Date:  2011-07-06       Impact factor: 3.090

Review 8.  Macrolides: From Toxins to Therapeutics.

Authors:  Kiersten D Lenz; Katja E Klosterman; Harshini Mukundan; Jessica Z Kubicek-Sutherland
Journal:  Toxins (Basel)       Date:  2021-05-12       Impact factor: 4.546

9.  Screening paediatric rectal forms of azithromycin as an alternative to oral or injectable treatment.

Authors:  Tina Kauss; Karen Gaudin; Alexandra Gaubert; Boubakar Ba; Serena Tagliaferri; Fawaz Fawaz; Jean-Louis Fabre; Jean-Michel Boiron; Xavier Lafarge; Nicholas J White; Piero L Olliaro; Pascal Millet
Journal:  Int J Pharm       Date:  2012-07-30       Impact factor: 5.875

10.  Pharmaceutical development and optimization of azithromycin suppository for paediatric use.

Authors:  Tina Kauss; Alexandra Gaubert; Chantal Boyer; Boubakar B Ba; Muriel Manse; Stephane Massip; Jean-Michel Léger; Fawaz Fawaz; Martine Lembege; Jean-Michel Boiron; Xavier Lafarge; Niklas Lindegardh; Nicholas J White; Piero Olliaro; Pascal Millet; Karen Gaudin
Journal:  Int J Pharm       Date:  2012-12-03       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.